Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M803125200 on October 1, 2008

J. Biol. Chem., Vol. 283, Issue 48, 33569-33577, November 28, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
283/48/33569    most recent
M803125200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Malka, Y.
Right arrow Articles by Henis, Y. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malka, Y.
Right arrow Articles by Henis, Y. I.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Ligand-independent Homomeric and Heteromeric Complexes between Interleukin-2 or -9 Receptor Subunits and the {gamma} Chain*

Yaniv Malka{ddagger}, Tekla Hornakova§12, Yohan Royer§13, Laurent Knoops§, Jean-Christophe Renauld§, Stefan N. Constantinescu§4, and Yoav I. Henis{ddagger}5

From the {ddagger}Department of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel and the §Ludwig Institute for Cancer Research and de Duve Institute, Université Catholique de Louvain, Brussels B-1200, Belgium

Signaling via interleukin-2 (IL-2) and interleukin-9 receptors (IL-2R and IL-9R) involves heteromeric interactions between specific interleukin receptor subunits, which bind Janus kinase 1 (JAK1) and the JAK3 binding common {gamma} chain ({gamma}c). The potential existence and roles of homomeric and heteromeric complexes before ligand binding and their modulation by ligand and JAK3 are unclear. Using computerized antibody-mediated immunofluorescence co-patching of epitope-tagged receptors at the surface of live cells, we demonstrate that IL-2Rβ, IL-9R{alpha}, and {gamma}c each display a significant fraction of ligand-independent homomeric complexes (24-28% co-patching), whereas control co-patching levels with unrelated receptors are very low (7%). Heteromeric complex formation of IL2-Rβ or IL-9R{alpha} with {gamma}c is also observed in the absence of ligand (15-30%). Ligand binding increases this hetero-oligomerization 2-fold but does not affect homo-oligomerization. Co-expression of IL-2R{alpha} does not affect the hetero-oligomerization of IL-2Rβ and {gamma}c. Recruitment of {gamma}c into heterocomplexes is partly at the expense of its homo-oligomerization, suggesting that a functional role of the latter may be to keep the receptors inactive in the absence of ligand. At the same time, the preformed complexes between {gamma}c and IL-2Rβ or IL-9R{alpha} promote signaling by the JAK3 A572V mutant without ligand, supporting a pathophysiological role for the constitutive oligomerization in triggering ligand-independent activation of JAK3 (and perhaps other JAK mutants) mutants identified in several human cancers.


Received for publication, April 23, 2008 , and in revised form, September 18, 2008.

* This research was supported in part by a grant from the Israeli Ministry of Health Chief Scientist's Office (to Y. I. H.). This work was also supported by the Fonds National de la Recherche Scientifique (Belgium), the Salus Sanguinis Foundation, the Action de Recherche Concertée MEXP31C1 (University Catholique de Louvain), the Fondation Contre le Cancer (Brussels), PAI Program BCHM61B5 (Belgium), and the Atlantic Philantropies, New York (to S. N. C.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 These authors were equal contributors.

2 Supported by Télévie.

3 Supported by a Mandat d'Aspirant of the Fonds National de la Recherche Scientifique, Belgium.

4 A Research Associate of the Fonds National de la Recherche Scientifique, Belgium. To whom correspondence may be addressed: Ludwig Institute for Cancer Research, Brussels B-1200, Belgium. Tel.: 32-2-764-7540; Fax: 32-2-764-6566; E-mail: stefan.constantinescu{at}bru.licr.org.

5 An incumbent of the Zalman Weinberg Chair in Cell Biology. To whom correspondence may be addressed. Tel.: 972-3-640-9053; Fax: 972-3-640-7643; E-mail: henis{at}post.tau.ac.il.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
T. Hornakova, J. Staerk, Y. Royer, E. Flex, M. Tartaglia, S. N. Constantinescu, L. Knoops, and J.-C. Renauld
Acute Lymphoblastic Leukemia-associated JAK1 Mutants Activate the Janus Kinase/STAT Pathway via Interleukin-9 Receptor {alpha} Homodimers
J. Biol. Chem., March 13, 2009; 284(11): 6773 - 6781.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement